Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A.
作者信息
Repessé Yohann, Costa Catherine, Palla Roberta, Moshai Elika Farrokhi, Borel-Derlon Annie, D'Oiron Roseline, Rothschild Chantal, El-Beshlawy Amal, Elalfy Mohsen, Ramanan Vijay, Eshghi Peyman, Oldenburg Johannes, Pavlova Anna, Rosendaal Frits R, Peyvandi Flora, Kaveri Srinivas V, Lacroix-Desmazes Sébastien
机构信息
CHU de Caen, Hematology Laboratory, Caen, France.
INSERM, U1237, GIP Cyceron, Caen, France.
出版信息
Haematologica. 2019 Aug;104(8):e369-e372. doi: 10.3324/haematol.2018.212001. Epub 2019 Jan 31.
Abstract
摘要
相似文献
1
Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A.
Haematologica. 2019 Aug;104(8):e369-e372. doi: 10.3324/haematol.2018.212001. Epub 2019 Jan 31.
2
To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Blood Rev. 2017 Sep;31(5):339-347. doi: 10.1016/j.blre.2017.07.001. Epub 2017 Jul 4.
3
Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry.
Haemophilia. 2015 Mar;21(2):e122-e124. doi: 10.1111/hae.12590. Epub 2015 Jan 27.
4
Factor VIII inhibitors.
Adv Exp Med Biol. 2001;489:65-73. doi: 10.1007/978-1-4615-1277-6_6.
5
Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates.
Haemophilia. 2007 Dec;13 Suppl 5:47-51. doi: 10.1111/j.1365-2516.2007.01571.x.
6
Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.
Haematologica. 2015 Feb;100(2):149-56. doi: 10.3324/haematol.2014.112821.
7
Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.
Haemophilia. 2014 Nov;20(6):e414-7. doi: 10.1111/hae.12521. Epub 2014 Oct 21.
8
Normal cleavage of von Willebrand factor by ADAMTS-13 in the absence of factor VIII in patients with severe hemophilia A.
J Thromb Haemost. 2013 Sep;11(9):1769-72. doi: 10.1111/jth.12299.
9
von Willebrand factor: what is its role in the immune response in haemophilia?
Haemophilia. 2011 Jan;17(1):e235-8. doi: 10.1111/j.1365-2516.2010.02277.x.
10
Factor VIII-von Willebrand factor binding defects in autosomal recessive von Willebrand disease type Normandy and in mild hemophilia A. New insights into factor VIII-von Willebrand factor interactions.
Acta Haematol. 2009;121(2-3):102-5. doi: 10.1159/000214849. Epub 2009 Jun 8.
引用本文的文献
1
The T follicular helper/T follicular helper regulatory pathway in FVIII immune responses in mice.
Blood. 2025 Aug 21;146(8):998-1010. doi: 10.1182/blood.2025029470.
2
Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies.
Front Immunol. 2020 Jan 17;10:3078. doi: 10.3389/fimmu.2019.03078. eCollection 2019.
本文引用的文献
1
A factor VIII-nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation.
Blood. 2018 Sep 13;132(11):1193-1197. doi: 10.1182/blood-2018-01-829523. Epub 2018 Jul 31.
2
Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.
Haematologica. 2018 Jan;103(1):179-189. doi: 10.3324/haematol.2017.174706. Epub 2017 Oct 12.
3
Biological considerations of plasma-derived and recombinant factor VIII immunogenicity.
Blood. 2017 Jun 15;129(24):3147-3154. doi: 10.1182/blood-2016-11-750885. Epub 2017 Apr 21.
4
The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells.
Haematologica. 2017 Feb;102(2):271-281. doi: 10.3324/haematol.2016.148502. Epub 2016 Oct 6.
5
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.
N Engl J Med. 2016 May 26;374(21):2054-64. doi: 10.1056/NEJMoa1516437.
6
Dissecting intensive treatment as risk factor for inhibitor development in haemophilia.
Haemophilia. 2016 May;22(3):e241-4. doi: 10.1111/hae.12944. Epub 2016 Apr 14.
7
Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter.
Haematologica. 2013 Oct;98(10):1650-5. doi: 10.3324/haematol.2013.084665. Epub 2013 May 28.
8
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.
Blood. 2013 Feb 21;121(8):1446-54. doi: 10.1182/blood-2012-06-434803. Epub 2012 Dec 6.
9
Characterizing polymorphisms and allelic diversity of von Willebrand factor gene in the 1000 Genomes.
J Thromb Haemost. 2013 Feb;11(2):261-9. doi: 10.1111/jth.12093.
10
A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function.
Blood. 2012 Sep 20;120(12):2512-20. doi: 10.1182/blood-2012-02-412361. Epub 2012 Jul 31.
Zotero 插件